PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1678
https://www.valueinhealthjournal.com/article/S1098-3015(18)34980-5/fulltext
Title :
PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34980-5&doi=10.1016/j.jval.2018.09.1678
First page :
Section Title :
Open access? :
No
Section Order :
1045